Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 29;19(1):398.
doi: 10.1186/s12885-019-5558-8.

Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers

Iwona Sidorkiewicz  1   2 , Monika Zbucka-Krętowska  3 , Kamil Zaręba  4 , Emilia Lubowicka  5 , Monika Zajkowska  6 , Maciej Szmitkowski  6 , Ewa Gacuta  7 , Sławomir Ławicki  8
Affiliations

Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers

Iwona Sidorkiewicz et al. BMC Cancer. .

Abstract

Background: The search of useful serum biomarkers for the early detection of cervical cancers has been of a high priority. The activation of Macrophage-Colony Stimulating Factor (M-CSF) and Vascular Endothelial Growth Factor (VEGF) is likely involved in the pathogenesis and spread of cancer. We compared the plasma levels of M-CSF and VEGF to the ones of commonly accepted tumor markers CA 125and SCC-Ag in three groups of patients: 1. the cervical cancer group (patients with either squamous cell carcinoma or adenocarcinoma); 2. the cervical dysplasia group; 3. the control group.

Methods: This cohort study included 100 patients with cervical cancer and 55 patients with cervical dysplasia. The control group consisted of 50 healthy volunteers. The plasma levels of VEGF and M-CSF were determined using ELISA, while CA 125 and SCC-Ag concentrations were obtained by the chemiluminescent microparticle immunoassay (CMIA).

Results: The median levels of M-CSF and VEGF as well as CA 125 and SCC-Ag in the entire group of cervical cancer patients, were significantly different compared to the healthy women group. In case of both the squamous cell carcinoma and the adenocarcinoma groups, plasma levels of M-CSF and VEGF were higher compared to the control group. No significant differences in the studied parameters between the squamous cell carcinoma and the adenocarcinoma group were observed. The highest sensitivity and specificity were obtained for VEGF (81.18 and 76.00%, respectively) and SCC-Ag (81.18%; 74.00%) in the squamous cell carcinoma group and for VEGF (86.67%; 76.00%) in the adenocarcinoma group. The area under the ROC curve for VEGF was the largest in the adenocarcinoma group followed by the squamous cell carcinoma group (0.9082 and 0.8566 respectively).

Conclusions: Obtained results indicate a possible clinical applicability and a high diagnostic power for the combination of MSC-F, VEGF, CA 125 and SCC-Ag in the diagnosis of both studied types of cervical cancer.

Keywords: Adenocarcinoma; Cervical cancer; M-CSF; Serum marker; Squamous cell carcinoma; Tumor marker; VEGF.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

All procedures performed in the studies involving human participants were in accordance with the ethical standard of the ethical committee at Medical University of Bialystok (R-I-002/239/2014) and written informed consent was obtained from each patient for research purposes.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Scatterplots of the studied parameters
Fig. 2
Fig. 2
Diagnostic criteria of ROC curve for tested parameters in adenocarcinoma cervical cancer group
Fig. 3
Fig. 3
Diagnostic criteria of ROC curve for tested parameters in combination with CA 125 and SCC-Ag in adenocarcinoma cervical cancer group
Fig. 4
Fig. 4
Diagnostic criteria of ROC curve for tested parameters in squamous cell cervical cancer group
Fig. 5
Fig. 5
Diagnostic criteria of ROC curve for tested parameters in combination with CA 125 and SCC-Ag in squamous cell cervical cancer group
See this image and copyright information in PMC

References

    1. Small W, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, et al. Cervical cancer: a global health crisis. Cancer. 2017;123(13):2404–2412. - PubMed
    1. Hillemanns P, Soergel P, Hertel H, Jentschke M. Epidemiology and early detection of cervical Cancer. Oncol Res Treat. 2016;39(9):501–506. - PubMed
    1. Carter SM, Williams J, Parker L, Pickles K, Jacklyn G, Rychetnik L, et al. Screening for cervical, prostate, and breast Cancer: interpreting the evidence. Am J Prev Med. 2015;49(2):274–285. - PubMed
    1. Aminisani N, Armstrong BK, Egger S, Canfell K. Impact of organised cervical screening on cervical cancer incidence and mortality in migrant women in Australia. BMC Cancer. 2012;12:491. - PMC - PubMed
    1. Kim JH, Kim IW, Kim YW, Park DC, Lee KH, Ahn TG, et al. Comparison of single-, double- and triple-combined testing, including pap test, HPV DNA test and cervicography, as screening methods for the detection of uterine cervical cancer. Oncol Rep. 2013;29(4):1645–1651. - PubMed

MeSH terms